Diabetes Prevention Program Outcomes Study
Office of Research on Women's Health (ORWH)
University of Tennessee Health Science Center

      The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an
      intensive lifestyle or metformin to prevent or delay the development of diabetes in a high
      risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended
      early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced
      diabetes onset by 31%.

      DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable
      DPP participants. This group of participants is nearly 50% minority and represents the
      largest IFG/IGT population ever studied. Clinically important research questions remain that
      focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course
      of precisely known new onset diabetes, in particular regarding microvascular disease, CVD
      risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in
      minority populations.

      The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of
      the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and
      high degree of study retention and adherence (~85% of the DPPOS cohort continues to attend
      annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on
      cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and
      import.
    
Behavioral